Please login to the form below

Not currently logged in
Email:
Password:

blinatumomab

This page shows the latest blinatumomab news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Amgen has gained EU marketing approval to extend use of Blincyto (blinatumomab) in children with acute lymphoblastic leukemia (ALL), putting it into direct competition with Novartis’new CAR-T treatment Kymriah.

Latest news

More from news
Approximately 4 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics